See more : AYO Technology Solutions Limited (AYO.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Allied Biotech Corporation (1780.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allied Biotech Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Arcimoto, Inc. (FUVV) Income Statement Analysis – Financial Results
- StoneBridge Acquisition Corporation (APACW) Income Statement Analysis – Financial Results
- PT Sekar Laut Tbk (SKLT.JK) Income Statement Analysis – Financial Results
- Tenaga Nasional Berhad (5347.KL) Income Statement Analysis – Financial Results
- Canon Inc. (7751.T) Income Statement Analysis – Financial Results
Allied Biotech Corporation (1780.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.altratene.com
About Allied Biotech Corporation
Allied Biotech Corporation manufactures and sells carotenoids worldwide. Its products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. The company also provides Canthaxanthin, which offers a range of shades of reddish orange for food and beverage applications; Lutein, a carotenoid that provides a range of green leafed vegetables, such as spinach, kale, broccoli, and egg yolks.; and Nano Coenzyme Q10, an antioxidant, which is used in the transformation of energy in the body. It serves food, beverage, dietary supplement, and feed industries. Allied Biotech Corporation was founded in 2001 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 720.43M | 716.75M | 676.76M | 618.07M | 0.00 |
| Cost of Revenue | 473.99M | 445.70M | 418.71M | 376.91M | 0.00 |
| Gross Profit | 246.44M | 271.05M | 258.05M | 241.15M | 0.00 |
| Gross Profit Ratio | 34.21% | 37.82% | 38.13% | 39.02% | 0.00% |
| Research & Development | 26.09M | 24.56M | 25.74M | 24.57M | 0.00 |
| General & Administrative | 54.75M | 55.59M | 46.27M | 49.48M | 0.00 |
| Selling & Marketing | 76.88M | 89.12M | 74.38M | 63.37M | 0.00 |
| SG&A | 131.64M | 144.71M | 120.64M | 112.85M | 0.00 |
| Other Expenses | 0.00 | 91.71M | -84.49M | 2.81M | 0.00 |
| Operating Expenses | 157.73M | 169.26M | 146.38M | 137.41M | 0.00 |
| Cost & Expenses | 631.72M | 614.96M | 565.09M | 514.33M | 0.00 |
| Interest Income | 15.63M | 5.30M | 1.65M | 5.14M | 11.43M |
| Interest Expense | 12.96M | 11.75M | 11.25M | 9.00M | 6.51M |
| Depreciation & Amortization | 69.45M | 71.76M | 65.24M | 61.63M | 0.00 |
| EBITDA | 204.79M | 270.55M | 94.06M | 173.32M | 199.14M |
| EBITDA Ratio | 28.43% | 37.75% | 13.90% | 28.04% | 0.00% |
| Operating Income | 88.71M | 198.79M | 28.83M | 111.70M | 0.00 |
| Operating Income Ratio | 12.31% | 27.74% | 4.26% | 18.07% | 0.00% |
| Total Other Income/Expenses | 33.67M | -13.76M | -94.09M | -2.22M | 2.04M |
| Income Before Tax | 122.38M | 185.04M | 17.58M | 101.53M | 0.00 |
| Income Before Tax Ratio | 16.99% | 25.82% | 2.60% | 16.43% | 0.00% |
| Income Tax Expense | 24.97M | 38.29M | 4.54M | 22.05M | 0.00 |
| Net Income | 97.41M | 146.74M | 13.04M | 79.47M | 0.00 |
| Net Income Ratio | 13.52% | 20.47% | 1.93% | 12.86% | 0.00% |
| EPS | 1.02 | 1.54 | 0.14 | 0.84 | 1.13 |
| EPS Diluted | 1.01 | 1.53 | 0.14 | 0.83 | 1.12 |
| Weighted Avg Shares Out | 95.73M | 95.38M | 95.33M | 94.61M | 94.85M |
| Weighted Avg Shares Out (Dil) | 95.97M | 95.78M | 95.37M | 95.75M | 95.11M |
Source: https://incomestatements.info
Category: Stock Reports